It has been reported that monotherapy with ABT-263 (navitoclax, targeted to inhibit BCL-2 and BCL-XL) [13] or ABT-199 (venetoclax, targeted to inhibit BCL-2) [14] is effective in chronic lymphocytic leukemia (CLL) and small cell lung cancer (SCLC) in clinical trials [15–17], and venetoclax has been approved by the FDA for del17p CLL patients [18, 19]. This evidence concerns the gene BCL2 and small cell lung carcinoma.